

# Thomas Karagiannis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115814/publications.pdf>

Version: 2024-02-01

38  
papers

2,658  
citations

430843

18  
h-index

330122

37  
g-index

38  
all docs

38  
docs citations

38  
times ranked

3238  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 262.	3.9	749
2	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e1369-e1369.	2.3	356
3	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 361, k1310.	2.3	294
4	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	3.9	182
5	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 984-993.	4.4	176
6	Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 138-146.	2.4	96
7	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	6.3	93
8	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	4.4	79
9	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	4.4	71
10	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	4.4	61
11	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	2.8	61
12	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	4.4	54
13	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1857-1868.	4.4	44
14	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , 2016, 52, 458-480.	2.3	42
15	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 169, 165.	3.9	38
16	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	4.4	33
17	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 584-592.	3.4	27
18	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 61-67.	3.2	26

#	ARTICLE	IF	CITATIONS
19	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2017, 18, 843-851.	1.8	19
20	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114.	4.4	19
21	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open, 2016, 6, e012185.	1.9	18
22	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2395-2401.	4.4	18
23	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. Diabetes, Obesity and Metabolism, 2021, 23, 822-831.	4.4	17
24	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 2016, 7, 36-38.	2.4	13
25	Metformin exposure and survival in head and neck cancer: A large population-based cohort study. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 588-594.	1.5	13
26	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. European Journal of Haematology, 2017, 98, 563-568.	2.2	10
27	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289.	1.9	10
28	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Research and Clinical Practice, 2021, 177, 108921.	2.8	10
29	Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta-analysis. Diabetic Medicine, 2019, 36, 557-568.	2.3	9
30	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. Journal of General Internal Medicine, 2020, , 1.	2.6	7
31	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence, 2017, Volume 12, 1-10.	4.7	5
32	Premixed insulin regimens for type 2 diabetes. Endocrine, 2016, 51, 387-389.	2.3	2
33	Meta-analysis of artificial pancreas trials: methodological considerations. Lancet Diabetes and Endocrinology, 2017, 5, 685.	11.4	2
34	Authors' reply to Scheffel and Schaan. BMJ, The, 2012, 344, e2922-e2922.	6.0	1
35	Review: Sodium-glucose cotransporter 2 inhibitors reduce HbA <sub>1c</sub> and weight but increase infections. Annals of Internal Medicine, 2014, 160, JC10.	3.9	1
36	In type 2 diabetes, weekly semaglutide reduced HbA <sub>1c</sub> and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine, 2018, 168, JC46.	3.9	1

#	ARTICLE	IF	CITATIONS
37	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2021, 174, 141.	3.9	1
38	Most add-on therapies to metformin have similar effects on HbA1c. <i>Evidence-Based Medicine</i> , 2016, 21, 223-223.	0.6	0